GlassScriptPhysician profile
Raymel Hernandez
NPI 1598307613
$103,104.06
in general payments reported to CMS, 2019-2025
39 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,244 · 2022: $1,122 · 2023: $31K · 2024: $25K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Travel and Lodging: $19K · Consulting Fee: $8,670 · Food and Beverage: $7,930 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,520 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,130.46 |
| Travel and Lodging | $19,293.08 |
| Consulting Fee | $8,669.50 |
| Food and Beverage | $7,930.28 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,520.00 |
| Education | $194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $30,734.95 | 2023-2025 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $20,686.66 | 2022-2025 | |
| Janssen Biotech, INC. | $16,694.97 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Pfizer INC. | $9,802.33 | 2021-2025 | |
| Astellas Pharma US INC | $8,592.84 | 2021-2025 | Xtandi, Padcev |
| Dendreon Pharmaceuticals LLC | $7,849.67 | 2021-2025 | Provenge |
| Exelixis INC. | $5,005.12 | 2021-2025 | Cabometyx |
| Janssen Scientific Affairs, LLC | $562.50 | 2024 | Erleada |
| Genzyme Corporation | $442.14 | 2021-2022 | |
| Seagen INC. | $354.77 | 2021-2025 | Padcev |
| Eisai INC. | $328.23 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $228.16 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $201.33 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $158.01 | 2024-2025 | |
| Daiichi Sankyo INC. | $131.31 | 2021-2024 | Enhertu |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $116.78 | 2024-2025 | Enhertu, Lynparza |
| Taiho Oncology, INC. | $105.64 | 2024-2025 | |
| Incyte Corporation | $103.13 | 2025 | Pemazyre, Monjuvi, Niktimvo |
| Genentech USA, INC. | $101.31 | 2021-2024 | Tecentriq |
| Kite Pharma, INC. | $97.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.06 | 2024-2025 | Opdivo, Krazati |
| Merck Sharp & Dohme LLC | $82.13 | 2023-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $75.07 | 2024-2025 | Iclusig, Ninlaro, Fruzaqla |
| Servier Pharmaceuticals LLC | $73.58 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $56.09 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $50.29 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Beone Medicines USA, INC. | $48.76 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $35.25 | 2024-2025 | Brukinsa, Tevimbra |
| Sobi, INC | $34.24 | 2025 | |
| Coherus Oncology, INC. | $34.20 | 2024 | |
| Tersera Therapeutics LLC | $33.27 | 2024 | Zoladex |
| Tolmar, INC. | $30.63 | 2024-2025 | Eligard, Rubraca |
| Immunocore Limited | $28.56 | 2025 | Kimmtrak |
| Sumitomo Pharma America, INC. | $28.23 | 2024 | Orgovyx |
| Pharmaand Gmbh | $26.58 | 2025 | Rubraca |
| Adc Therapeutics America, INC. | $23.27 | 2024 | |
| Array Biopharma INC | $21.39 | 2024 | Mektovi, Braftovi, Tukysa |
| Caris Mpi, INC. | $19.04 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $15.54 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymel Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.